Glenmark Pharmaceuticals Expands Portfolio with Launch of Vancomycin Hydrochloride for Injection

Glenmark Pharmaceuticals has announced the launch of Vancomycin Hydrochloride for Injection, a critical antibiotic used to treat severe bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is often considered a "drug of last resort" due to its effectiveness against resistant strains. This launch underscores Glenmark's commitment to providing essential medications for serious infections. The product is available in various strengths, aligning with Glenmark's strategy to enhance its presence in the global pharmaceutical market by offering high-quality, affordable treatments.

 

Source: Business Wire